Access to innovative medicines by pharma companies: Sustainable initiatives for global health or useful advertisement?

References

• Abou-Gharbia, M., & Childers, W. E. (2014). Discovery of innovative therapeutics: Today’s realities and tomorrow’s vision. 2. Pharma’s challenges and their commitment to innovation. Journal of Medicinal Chemistry, 57(13), 5525–5553. doi: 10.1021/jm401564r
   PubMed Web of Science ®Google Scholar
• Almeida, A. O., & Viana Freire, M. V. (2018). Right to health in Brazil: Use of reserves and basic human dignity in the decisions of the Brazilian Superior Court of Justice (2010–2016) [ Direito à saúde no Brasil: Reserva do possível e mínimo existencial nas decisões do superior Tribunal de Justiça (2010–2016)]. Revista de Direito Sanitario, 19(2), 55–77. doi: 10.11606/issn.2316-9044.v19i2p55-77
   Web of Science ®Google Scholar
• Anonymous. (2018). Access accelerated year two report: Working together to translate words into actions. Retrieved from accessaccelerated.org/initiatives
   Google Scholar
• ATM. (2017). Access to medicine index 2018 methodology 2017. Retrieved from www.accesstomedicineindex.org
   Google Scholar
• ATM. (2018). Access to medicine index 2018. Retrieved from www.accesstomedicineindex.org
   Google Scholar
• Baker, B. K., & Ombaka, E. (2009). The danger of in-kind drug donations to the global fund. The Lancet, 373(9670), 1218–1221. doi: 10.1016/S0140-6736(08)61487-7
   PubMed Web of Science ®Google Scholar
• Bardin, L. (1977). Content analysis. São Paulo: Livraria Martins Fontes.
   Google Scholar
• Barton, J. H. (2002). Research-tool patents: Issues for health in the developing world. Bulletin of the World Health Organization, 80(2), 121–125.
   PubMed Web of Science ®Google Scholar
• Bélisle-Pipon, J.-C., & Williams-Jones, B. (2015). Drug familiarization and therapeutic misconception via direct-to-consumer information. Journal of Bioethical Inquiry, 12(2), 259–267. doi: 10.1007/s11673-015-9634-8
   PubMed Web of Science ®Google Scholar
• Biehl, J., Socal, M. P., Gauri, V., Diniz, D., Medeiros, M., Rondon, G., & Amon, J. J. (2019). Judicialization 2.0: Understanding right-to-health litigation in real time. Global Public Health, 14(2), 190–199. doi: 10.1080/17441692.2018.1474483
   PubMed Web of Science ®Google Scholar
• Birn, A.-E. (2005). Gates’s grandest challenge: Transcending technology as public health ideology. Lancet, 366(9484), 514–519. doi: 10.1016/S0140-6736(05)66479-3
   PubMed Web of Science ®Google Scholar
• Brammer, S., & Millington, A. (2005). Corporate reputation and philanthropy: An empirical analysis. Journal of Business Ethics, 61(1), 29–44. doi: 10.1007/s10551-005-7443-4
   Web of Science ®Google Scholar
• Cohen, J. P., Silva, L., Cohen, A., Awatin, J., & Sturgeon, R. (2016). Progress report on neglected tropical disease drug donation programs. Clinical Therapeutics, 38(5), 1193–1204. doi: 10.1016/j.clinthera.2016.02.031
   PubMed Web of Science ®Google Scholar
• Cole, C. B., Trolle, S., & Edwards, D. J. (2018). Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and development. Health Research Policy and Systems, 16(1). doi: 10.1186/s12961-018-0332-y
   PubMedGoogle Scholar
• Collins, M. (1993). Global corporate philanthropy–marketing beyond the call of duty? European Journal of Marketing, 27(2), 46–58. doi: 10.1108/EUM0000000000651
   Google Scholar
• da Fonseca, E. M. (2018). How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health–industry complex in Brazil. Global Public Health, 13(4), 489–502. doi: 10.1080/17441692.2017.1396354
   PubMed Web of Science ®Google Scholar
• Doh, J. P., & Guay, T. R. (2004). Globalization and corporate social responsibility: How non-governmental organizations influence labor and environmental codes of conduct. In Management and international review (pp. 7–29). Gabler Verlag, Wiesbaden: Springer.
   Google Scholar
• Dyllick, T., & Hockerts, K. (2002). Beyond the business case for corporate sustainability. Business Strategy and the Environment, 11(2), 130–141. doi: 10.1002/bse.323
   Google Scholar
• Frost, L. J., & Reich, M. R. (2008). Access: How do good health technologies get to poor people in poor countries? Cambridge, Mass: Harvard University Press.
   Google Scholar
• Ganguli, A., Clewell, J., & Shillington, A. C. (2016). The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: A targeted systematic review. Patient Preference and Adherence, 10, 711–725. doi: 10.2147/PPA.S101175
   PubMed Web of Science ®Google Scholar
• Gimenez, C., Sierra, V., & Rodon, J. (2012). Sustainable operations: Their impact on the triple bottom line. International Journal of Production Economics, 140(1), 149–159. doi: 10.1016/j.ijpe.2012.01.035
   Web of Science ®Google Scholar
• Herzog, L. (2017). No company is an Island. Sector-related responsibilities as elements of corporate social responsibility. Journal of Business Ethics, 146(1), 135–148. doi: 10.1007/s10551-015-2923-7
   Web of Science ®Google Scholar
• Hogerzeil, H. V. (2013). Big pharma and social responsibility—the access to medicine index. New England Journal of Medicine, 369(10), 896–899. doi: 10.1056/NEJMp1303723
   PubMed Web of Science ®Google Scholar
• Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., & de Joncheere, K. (2016). Intellectual property and local medicines production. WHO Drug Information, 30(2), 1–22.
   Google Scholar
• Jaruzelski, B., Loehr, J., & Holman, R. (2011). Why culture is key: The global innovation 1000. Strategy+ Business, 65, 1–16.
   Google Scholar
• Juneja, S., Gupta, A., Moon, S., & Resch, S. (2017). Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP). PLoS One, 12(5), e0177770. doi: 10.1371/journal.pone.0177770
   PubMed Web of Science ®Google Scholar
• Kim, H. (2015). Trouble spots in online direct-to-consumer prescription drug promotion: A content analysis of FDA warning letters. International Journal of Health Policy and Management, 4(12), 813. doi: 10.15171/ijhpm.2015.157
   PubMed Web of Science ®Google Scholar
• Kohler, J., Martinez, M., Petkov, M., & Sale, J. (2016). Corruption in the pharmaceutical sector: Diagnosing the challenges. (London: Transparency International UK, 2016); Transparency International. Transparency and Good Governance in Global Health.
   Google Scholar
• Kuek, V., Phillips, K., & Kohler, J. C. (2011). Access to medicines and domestic compulsory licensing: Learning from Canada and Thailand. Global Public Health, 6(2), 111–124. doi: 10.1080/17441690903575255
   PubMed Web of Science ®Google Scholar
• Lee, J.-Y., & Hunt, P. (2012). Human rights responsibilities of pharmaceutical companies in relation to access to medicines. The Journal of Law, Medicine & Ethics, 40(2), 220–233. doi: 10.1111/j.1748-720X.2012.00660.x
   PubMed Web of Science ®Google Scholar
• Leisinger, K. M. (2005). The corporate social responsibility of the pharmaceutical industry: Idealism without illusion and realism without resignation. Business Ethics Quarterly, 15(4), 577–594. doi: 10.5840/beq200515440
   PubMed Web of Science ®Google Scholar
• Levy, R. (1994). The role and value of pharmaceutical marketing. Archives of Family Medicine, 3(4), 327. doi: 10.1001/archfami.3.4.327
   PubMedGoogle Scholar
• Lozano, R., Carpenter, A., & Huisingh, D. (2015). A review of “theories of the firm” and their contributions to corporate sustainability. Journal of Cleaner Production, 106, 430–442. doi: 10.1016/j.jclepro.2014.05.007
   Web of Science ®Google Scholar
• McAlister, F. A., Lawson, F. M., Teo, K. K., & Armstrong, P. W. (2001). A systematic review of randomized trials of disease management programs in heart failure. The American Journal of Medicine, 110(5), 378–384. doi: 10.1016/S0002-9343(00)00743-9
   PubMed Web of Science ®Google Scholar
• Miller, S. M., Moos, W. H., Munk, B. H., & Munk, S. A. (2016). Managing the drug discovery process: How to make it more efficient and cost-effective. Retrieved from https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009653924&partnerID=40&md5=e0e41de56824b7317d7c820273e4b320
   Google Scholar
• Moran, M., Guzman, J., Ropars, A. L., & Illmer, A. (2010). The role of product development partnerships in research and development for neglected diseases. International Health, 2(2), 114–122. doi: 10.1016/j.inhe.2010.04.002
   PubMed Web of Science ®Google Scholar
• Nejati, M., & Ghasemi, S. (2013). Corporate social responsibility and organizational commitment: Empirical findings from a developing country. Journal of Global Responsibility, 4(2), 263–275. doi: 10.1108/JGR-01-2013-0001
   Google Scholar
• Nidumolu, R., Prahalad, C. K., & Rangaswami, M. R. (2009). Why sustainability is now the key driver of innovation. Harvard Business Review, 87(9), 56–64.
   Web of Science ®Google Scholar
• Perehudoff, S. K., Alexandrov, N. V., & Hogerzeil, H. V. (2019). Access to essential medicines in 195 countries: A human rights approach to sustainable development. Global Public Health, 14(3), 431–444. doi: 10.1080/17441692.2018.1515237
   PubMed Web of Science ®Google Scholar
• Peterson, D. K. (2018). Enhancing corporate reputation through corporate philanthropy. Journal of Strategy and Management, 11(1), 18–32. doi: 10.1108/JSMA-10-2016-0068
   Web of Science ®Google Scholar
• Quak, S., Heilbron, J., & Meijer, J. (2019). Ranking, coordination, and global governance: The case of the access to medicine index. Business and Politics, 21(2), 172–204. doi: 10.1017/bap.2018.22
   Web of Science ®Google Scholar
• Roberts, M. J., & Reich, M. R. (2002). Ethical analysis in public health. The Lancet, 359(9311), 1055–1059. doi: 10.1016/S0140-6736(02)08097-2
   PubMed Web of Science ®Google Scholar
• Rocha, M. de M., Vieira, D. G., Lima, G. B. A., De Andrade, E. P., & Quelhas, O. L. G. (2017). The risk of innovation: Measuring drug clinical development in Brazil. International Journal of Business Innovation and Research. Retrieved from http://www.scielo.cl/scielo.php?pid=S0718-27242012000300013&script=sci_arttext&tlng=en
   Google Scholar
• Rodwin, M. A. (2013). Institutional corruption and the pharmaceutical policy. Los Angeles, CA: Sage.
   Google Scholar
• Ross, J. S., & Kesselheim, A. S. (2013). Prescription-drug coupons—no such thing as a free lunch. New England Journal of Medicine, 369(13), 1188–1189. doi: 10.1056/NEJMp1301993
   PubMed Web of Science ®Google Scholar
• Sachs, J. D. (2015). The age of sustainable development. New York: Columbia University Press.
   Google Scholar
• Saiia, D. H., Carroll, A. B., & Buchholtz, A. K. (2003). Philanthropy as strategy: When corporate charity “begins at home”. Business & Society, 42(2), 169–201. doi: 10.1177/0007650303042002002
   Google Scholar
• Simchi-Levi, D., Kaminsky, P., & Simchi-Levi, E. (2004). Designing and Managing the Supply Chain: Concepts, Strategies, and Case Studies. Boston: Irwin McGraw-Hill.
   Google Scholar
• Steve, V. (2005). Zimbabweans make condom bangles. BBC News.
   Google Scholar
• Thorsteinsdóttir, H., Ovtcharenko, N., & Kohler, J. C. (2017). Corporate social responsibility to improve access to medicines: The case of Brazil. Globalization and Health, 13(1), doi: 10.1186/s12992-017-0235-7
   PubMedGoogle Scholar
• Turker, D. (2009). How corporate social responsibility influences organizational commitment. Journal of Business Ethics, 89(2), 189. doi: 10.1007/s10551-008-9993-8
   Web of Science ®Google Scholar
• Wang, T., & Bansal, P. (2012). Social responsibility in new ventures: Profiting from a long-term orientation. Strategic Management Journal, 33(10), 1135–1153. doi: 10.1002/smj.1962
   Web of Science ®Google Scholar
• Wazana, A. (2000). Physicians and the pharmaceutical industry: Is a gift ever just a gift? Jama, 283(3), 373–380. doi: 10.1001/jama.283.3.373
   PubMed Web of Science ®Google Scholar
• WHO. (2017). Responding to industry initiatives to increase access to medicines and other health technologies in countries. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Williams, O. D. (2012). Access to medicines, market failure and market intervention: A tale of two regimes. Global Public Health, 7(Suppl. 2), S127–S143. doi: 10.1080/17441692.2012.725753
   PubMedGoogle Scholar
• Wirtz, V. J., & Moucheraud, C. (2017). Beyond availability and affordability: How access to medicines affects non-communicable disease outcomes. The Lancet Public Health, 2(9), e390–e391. doi: 10.1016/S2468-2667(17)30168-8
   PubMed Web of Science ®Google Scholar
• Yin, R. (1994). Case study research: Design and methods (2nd ed.). Beverly Hills, CA: Sage.
   Google Scholar
• Zapatero Miguel, P. (2015). Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies. Global Public Health, 10(8), 901–916. doi: 10.1080/17441692.2015.1014824
   PubMed Web of Science ®Google Scholar